Fukuoka, Japan, October 18, 2022 /PRNewswire/ — EditForce, Inc. (“EditForce”), Fukuoka PrefectureRealized the world’s first RNA editing technology that can convert RNA editing bases from “U” to “C”, and demonstrated that this technology also works in human cells in joint research with Professor Takahiro NakamuraFaculty of Agriculture, Kyushu UniversityThis research opens up the possibility of editing gene mutations that could not be targeted with existing technologies, and is expected to contribute to the research and development of treatments for various genetic diseases. EditForce improves safety and editing efficiency in development activities to establish innovative gene therapy technologies. The study was published in the scientific journal Communications Biology. September 15th (September 16th JST), 2022.
Logo: https://kyodonewsprwire.jp/prwfile/release/M107232/202210117969/_prw_PI1fl_AXiGsGJ1.jpg
research summary
The genome present in each human cell consists of four nucleotide bases, A, C, G, and T, whose sequence contains the information necessary to construct the human body. Cells produce RNA consisting of four nucleotide bases, A, C, G, and U, based on the genome sequence, and produce proteins according to the RNA sequence. However, a single nucleotide change in the genome or her RNA sequence causes various diseases. Therapies for these diseases require single-nucleotide editing techniques that repair genomic or RNA mutations and put sequences back on track.
Genome editing technology is currently developing rapidly, but the development of RNA sequence editing technology is still limited. Especially for single-base substitutions, techniques for substituting “C” for “U” and “A” for “G” have been established, but other base substitutions have not yet been realized.
EditForce clarified the mechanism of RNA editing that replaces “U” with “C” in plants, and realized the world’s first RNA editing (base substitution) technology that replaces “U” with “C”. demonstrated that it works in human cells.
Base-editing techniques can be applied to treat diseases caused by single mutations, and the research’s ‘U-to-C’ RNA-editing technique has the potential to edit mutations that could not be targeted by existing methods. Open technology. Additionally, by repairing mutations through RNA editing without altering the genome sequence, EditForce will be able to provide safer treatments to patients. The company hopes that this technology will improve safety and editing efficiency in development activities and establish new gene therapies.
This work was supported by a research grant for young researchers funded by Yamanashi Prefecture.
Article information
Ichinose M., Kawabata M., Akiwa Y., Shimajiri Y., Nakamura I., Tamai T., Nakamura T., Yagi Y. and Gutmann B. “U-to-C RNA editing bacteria by synthetic PPR-DYW proteins.” and Human Cultured Cells,” Commun Biol. 5, 968 (2022).
About Edit Force
Edit Force Co., Ltd. Kyushu UniversityA startup that develops its own DNA/RNA editing technology (PPR platform technology) ), was established in May 2015 KISCO Corporation and Prof. Takahiro Nakamura
Former Edit Force Chancellor and current Scientific Advisor of Kyushu University, he is funded by companies and funds with a track record of investing in life sciences and biotechnology. EditForce aims at drug discovery applying PPR technology through joint research with universities and private companies.
For more information, please visit https://www.editforce.co.jp/.
Pentatricopeptide repeat (PPR) protein platform technologyPPRs are proteins found in plants that regulate gene expression by binding sequence-specifically to DNA and RNA. PPR proteins are also found in humans and yeast and have similar functions.Prof. Takahiro Nakamura and Dr.
Yuusuke Yagi
CTO, CTO of EditForce, focused on PPR proteins, elucidated the mechanisms that determine sequence specificity, and established techniques to create different PPR proteins, each of which binds to a specific target DNA or RNA sequence. Furthermore, by fusing with effector proteins, it is possible to manipulate and modify the target genome and RNA inside and outside the cell.
Comments
Post a Comment